Latest Operating Costs News

Botanix Pharmaceuticals reports a surge in Sofdra sales driving revenue to $16.5 million, yet the company records a $33.2 million loss amid expanded marketing and operational costs. A $45 million capital raise aims to support growth and supply chain improvements.

DigitalX Limited reported a narrower half-year loss and increased revenues, underpinned by a strategic pivot to a Bitcoin-first treasury model and operational cost discipline.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

GLG Corp Ltd reported an 18.7% drop in revenue to USD 54.1 million for the half year ended December 2025, resulting in a net loss amid challenging macroeconomic conditions and tariff pressures. Despite operational efficiencies improving gross margins, the company refrained from declaring an interim dividend.

Hydrix Limited reported a 14% revenue decline and a sharp increase in net loss for H1 2026, raising concerns about its financial stability despite securing a major contract.

Mach7 Technologies reported a 23% drop in revenue to $13.65 million for H1 FY26, alongside a sharp increase in net loss to $5.75 million, as it embarks on a strategic commercial reset and expands its Asia-based engineering capabilities.

DorsaVi Limited reported a steep increase in its half-year loss to $3.6 million, driven by declining revenues and a sharp rise in operating costs, despite raising over $5 million in fresh capital.

Patrys Limited reported a near doubling of its half-year loss to $3.02 million, driven by restructuring and a strategic pivot including the acquisition of Reliis Pty Ltd. The company is advancing a dual-platform biotech strategy combining a clinical-stage CNS asset with its proprietary antibody platform.

Gryphon Capital Income Trust reported a robust half-year profit increase alongside successful capital raises, positioning the fund for expanded investment in Australian RMBS and ABS markets.

Vectus Biosystems reports a narrowed half-year loss as it advances clinical drug VB0004 and nears a key asset sale to XORTX Therapeutics.

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

GTN Limited reported a 14.7% revenue decline to $82.5 million and a significant net loss of $40.9 million for the half-year ended December 2025, driven by a $41.5 million impairment charge. The company also announced a $43.9 million return of capital and a strategic exit from aviation operations in Australia and Canada.